Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: Are they associated with cardiovascular disease?

Kidney and Blood Pressure Research

Volumn 32, Issue 4, 2009, Pages 276-283

  Peiskerova M ^a   Kalousova M ^a   Kratochvilova M ^a   Dusilova Sulkova S ^c   Uhrova J ^a   Bandur S ^b   Malbohan, I M ^a   Zima, T ^a   Tesa, V ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Calcitriol; Cardiovascular disease; Chronic kidney disease; Fibroblast growth factor 23; Metalloproteinases; Oxidative stress

Indexed keywords

ALBUMIN; CALCITRIOL; FIBROBLAST GROWTH FACTOR 23; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PARATHYROID HORMONE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PREGNANCY ASSOCIATED PROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

AGED; AGING; BIOLOGICAL MARKERS; CALCITRIOL; CARDIOVASCULAR DISEASES; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LIPIDS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PARATHYROID HORMONE; SERUM ALBUMIN; SEX CHARACTERISTICS; VITAMIN D; VITAMINS;

EID: 70349606516     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000243050     Document Type: Article

References (32)

1. Inaba M, Okuno S, Imanishi Y, et al: Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006; 17: 1506-1513.
2. Krajisnik T, Björklund P, Marsell R, et al: Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131.
3. Emmett M: What does serum fibroblast growth factor 23 do in hemodialysis patients? Kidney Int 2008; 73: 3-5.
4. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524.
5. Westerberg PA, Linde T, Wikström B, Ljunggren O, Stridsberg M, Larsson TE: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3202-3207.
6. Levin A, Li YC: Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005; 68: 1973-1981.
7. Gutiérrez OM, Mannstadt M, Isakova T, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
8. Bayes-Genis A, Conover CA, Overgaard MT, et al: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-1029.
9. Chow AK, Cena J, Schulz R: Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007; 152: 189-205.
10. Qin X, Corriere MA, Matrisian LM, Guzman RJ: Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 2006; 1510-1516.
11. Martos R, Baugh J, Ledwidge M, et al: Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888-895.
12. Viappiani S, Nicolescu AC, Holt A, et al: Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009; 77: 826-834.
13. Ali MA, Schulz R: Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front Biosci 2009; 14: 699-716.
14. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR: Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110: 3480-3487.
15. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH: Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006; 20: 1898-1900.
16. Timms PM, Mannan N, Hitman GA, et al: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 787-796.
17. Razzaque MS, Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194: 1-10.
18. Gutierrez O, Isakova T, Rhee E, et al: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
19. Shigematsu T, Kazama JJ, Yamashita T, et al: Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256.
20. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H, et al: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
21. Imanishi Y, Kobayashi K, Kawata T, Inaba M, Nishizawa Y: Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases. Ther Apher Dial 2007; 11(suppl 1):S32-S37.
22. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620.
23. Zittermann A, Dembinski J, Stehle P: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-112.
24. Teng M, Wolf M, Ofsthun MN, et al: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
25. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K, et al: Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403. (Pubitemid 351350586)
26. Andress D: Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67: 1999-2012.
27. Sapienza P, di Marzo L, Borrelli V, et al: Basic fibroblast growth factor mediates carotid plaque instability through metalloproteinase- 2 and -9 expression. Eur J Vasc Endovasc Surg 2004; 28: 89-97.
28. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA: The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 1092-1105.
29. Jono S, McKee MD, Murry CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87:E10-E17.
30. Ferrari SL, Bonjour JP, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524.
31. Kestenbaum B, Sampson JN, Rudser KD, et al: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
32. Fliser D, Kollerits B, Neyer U, et al: Fibroblast growth factor 23 (FGF-23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608.